A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
- Conditions
- HypertensionChronic Kidney Disease
- Interventions
- Drug: Placebo to BAY3283142
- Registration Number
- NCT05491642
- Lead Sponsor
- Bayer
- Brief Summary
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly.
In people with CKD, the kidneys do not remove wastes and extra fluid from the blood as well as they should. High blood pressure makes it more likely that the CKD gets worse.
The study treatment BAY3283142 is under development for treating CKD. It activates a protein called soluble guanylate cyclase (sGC) that generates cGMP - a molecule that relaxes blood vessels and is thought to have beneficial effects in CKD.
The participants do not benefit from this study. However, the study will provide information on how to use BAY3283142 in subsequent studies in people with CKD. As many people with CKD do also suffer from high blood pressure, this study is done in people with mild to moderate high blood pressure to safeguard the use of BAY3283142 in people with CKD in later studies.
The main purpose of this study is to learn how safe different single and multiple doses of the study treatment BAY3283142 are compared to placebo in male and female participants (after menopause) with mild to moderate high blood pressure. A placebo is a treatment that looks like a medicine but does not have any medicine in it.
To answer this, the researchers will compare the number of participants who have medical problems after taking BAY3283142 to those treated with placebo. Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments.
Dependent on the treatment group, the participants will either take BAY3283142 or placebo as tablet once or twice a day. Patients will take one dose for 6 days and will then be switched to a higher dose for additional 6 days. In summary, three different dose combinations consisting of two different doses each will be tested.
Participants will be in the study for up to 7 weeks, including 12 treatment days (6 per dose step). They will stay in-house for 17 days starting two days before intake of the study treatment. In addition, one visit before and one visit after the in-house phase to the study site is planned.
During the study, the study team will:
* Check vital signs
* Take blood and urine samples
* Examine the participants' heart health using electrocardiogram (ECG)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 56
- Participant must be 30 to 78 years of age inclusive, at the time of signing the informed consent.
- Participants with diagnosis of mild to moderate systemic arterial hypertension receiving stable treatment for ≥8 weeks before the screening visit with not more than 2 antihypertensive drugs (note: 2 antihypertensive drugs combined within one pill count as 2 antihypertensive drugs).
- Mean systolic blood pressure (SBP) 120 - 160 mm Hg and mean diastolic blood pressure (DBP) 70-95 mm Hg at screening (mean out of triplicate measurements after supine rest for 15 min at screening).
- Estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73 m^2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-Epi] formula) at screening and Study Day -2.
- Men and confirmed postmenopausal women.
-
Acute coronary syndrome (STEMI, NSTEMI, unstable angina, CABG, PCI, cardiac surgery).
-
Ventricular tachycardia, atrial fibrillation, sick sinus syndrome, WPW syndrome.
-
Thrombo-embolic events, e.g. stroke, TIA, deep vein thrombosis, pulmonary embolism.
-
Systemic diseases: cancer (with the exception of appropriately treated basal cell carcinomas of the skin or uterine carcinoma in situ), autoimmune diseases (including also topically treated autoimmune diseases such as atopic dermatitis).
-
Latent bleeding risk (diabetic retinopathy, history of gastrointestinal bleeding due to e.g. ulcers), inherited or acquired coagulopathies.
-
Orthostatic intolerance in the modified standing blood pressure procedure at screening.
-
Long-acting or short-acting nitrates or NO donors for any route including isosorbide dinitrate, isosorbide-5-mononitrate, pentaerythritol tetranitrate, nicorandil, nitrotriglyceride, molsidomin.
-
Phosphodiesterase-5 (PDE-5) inhibitors or other soluble guanylate cyclase (sGC) stimulators or activators.
-
Inhibitors of Uridine-5'-diphospho glucuronosyltransferase (UGT) 1A1, 1A3, 1A8 (e.g., probenecid) from 7 days before first study intervention until follow-up.
-
Signs of hepatic dysfunction at the screening visit or at randomization as indicated by at least one of the following:
- increases in isolated hepatic enzymes >1.3 fold ULN (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [AP], γ-GT).
- Bilirubin > 1.3 fold ULN.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Up-titration Scheme 3 BAY3283142 Participants will receive 12 days treatment in total. Up-titration Scheme 1 Placebo to BAY3283142 Participants will receive 12 days treatment in total. Up-titration Scheme 2 Placebo to BAY3283142 Participants will receive 12 days treatment in total. Up-titration Scheme 3 Placebo to BAY3283142 Participants will receive 12 days treatment in total. Up-titration Scheme 2 BAY3283142 Participants will receive 12 days treatment in total. Up-titration Scheme 1 BAY3283142 Participants will receive 12 days treatment in total.
- Primary Outcome Measures
Name Time Method Number of participants with treatment-emergent adverse events per treatment arm Up to 7 days after end of treatment with study intervention
- Secondary Outcome Measures
Name Time Method AUC in a dosing interval after multiple doses of BAY3283142 on Day 12 (AUCτ,md) Up to 24 hours post-dose Area under the concentration versus time curve in a dosing interval (AUCτ) after single dose of BAY3283142 on Day 1 Up to 24 hours post-dose AUCτ after single dose of BAY3283142 on Day 1 divided by dose (AUCτ/D) Up to 24 hours post-dose Maximum observed drug concentration in measured matrix (Cmax) after single dose of BAY3283142 on Day 1 Up to 24 hours post-dose Cmax after single dose of BAY3283142 on Day 1 divided by dose (Cmax/D) Up to 24 hours post-dose AUCτ,md after multiple doses of BAY3283142 on Day 12 divided by dose (AUCτ,md/D) Up to 24 hours post-dose Maximum observed drug concentration in measured matrix after multiple doses of BAY3283142 on Day 12 (Cmax,md) Up to 24 hours post-dose Cmax,md after multiple doses of BAY3283142 on Day 12 divided by dose (Cmax,md/D) Up to 24 hours post-dose
Trial Locations
- Locations (4)
Medical Center Comac Medical EOOD
🇧🇬Sofia, Bulgaria
Charité Research Organisation GmbH
🇩🇪Berlin, Germany
CTC North GmbH & Co. KG
🇩🇪Hamburg, Germany
CRS Clinical-Research-Services Mannheim GmbH
🇩🇪Mannheim, Baden-Württemberg, Germany